Most Read Articles
Pearl Toh, 08 Jun 2016
Middle East Respiratory Syndrome (MERS) patients have more severe illness and a higher mortality rate than non-MERS severe acute respiratory infection (SARI) patients, according to a study presented at the recent American Thoracic Society (ATS) International Conference 2016 held in San Francisco, California, US.
Rachel Soon, 04 Aug 2017

Investment in health crisis response systems during non-pandemic periods is crucial to combating the next inevitable flu pandemic, according to a government representative.

30 Apr 2016
New drug applications approved by US FDA as of 16 - 30 Apr 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
15 Jan 2017
New drug applications approved by US FDA as of 1 - 15 January 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Adjuvant chemotherapy, cardiac disease history predict PCE after radiation for NSCLC

10 Sep 2017
Lack of public awareness about the way lung cancer strikes is a big factor in delaying diagnosis and treatment

Pericardial effusion (PCE) is a common adverse side effect following thoracic radiation therapy (RT) for locally-advanced nonsmall cell lung cancer (NSCLC), a new study reveals. Additionally, PCE risk is increased by adjuvant chemotherapy.

The effects of intensity-modulated radiation therapy (IMRT) vs passive scattering proton beam therapy for locally advanced, inoperable NSCLC were assessed in 201 patients (56.2 percent male). Those with chest irradiation or PCE prior to treatment were excluded.

The primary study endpoint was development of PCE. Other outcomes included time to development – calculated from the start of RT – and overall survival (OS). Univariate and Multivariate Cox proportional hazards analyses were used to determine hazard ratios (HR) for PCE development.

Over a median follow-up of 23.9 months, participants received a median RT dose of 74 Gy and heart dose of 12.2 Gy. PCE was reported in 42.8 percent (n=86) of the patients, of which 40.3 percent (n=81) had grade 2 and 5.2 percent (n=5) had grade 3 PCE.

The 1- and 2-year cumulative PCE incidence rates were 31.4 and 45.4 percent, respectively, with a median time to development of 8.9 months.

The OS at 2 years was significantly higher in the PCE group than in those without PCE (69.0 vs 44.3 percent; p=0.012); at 5 years, the difference in corresponding OS rates decreased (43.3 vs 25.6 percent).

In multivariate analysis, heart volume receiving 35 Gy >10 percent (HR, 2.14; p=0.002), adjuvant chemotherapy (HR, 2.82; p<0.001) and history of cardiac disease (HR, 1.68; p=0.020) were all independent risk predictors for PCE.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 08 Jun 2016
Middle East Respiratory Syndrome (MERS) patients have more severe illness and a higher mortality rate than non-MERS severe acute respiratory infection (SARI) patients, according to a study presented at the recent American Thoracic Society (ATS) International Conference 2016 held in San Francisco, California, US.
Rachel Soon, 04 Aug 2017

Investment in health crisis response systems during non-pandemic periods is crucial to combating the next inevitable flu pandemic, according to a government representative.

30 Apr 2016
New drug applications approved by US FDA as of 16 - 30 Apr 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
15 Jan 2017
New drug applications approved by US FDA as of 1 - 15 January 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.